Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, said tricuspid valve treatments are a popular topic among cardiologists right now. TAVR research, meanwhile, remains as important as ever.

The Acurate neo2 TAVR valve has been used to treat severe aortic stenosis in other parts of the world for years. In the United States, however, the device has still not been approved for commercial use.  

New late-breaking data presented at TCT confirmed that the first FDA-approved TTVR system for TR is associated with a much better quality of life than medical therapy alone after one year.

New research presented at TCT combined data from the RHEIA and PARTNER 3 trials. “TAVR is a good option, and probably the best one, for an elderly woman," cardiologist Anna Sonia Petronio, MD, explained during the conference. 

Attendees cheered as lead investigator Philippe Généreux, MD, shared his team's findings at TCT 2024. “A major reset in our approach to severe asymptomatic AS is now warranted,” one veteran cardiologist said about the data. “The concept of watchful waiting is no longer appropriate."

The Evolut FX+ TAVR system, which already received FDA approval in March, was designed with improved coronary access in mind. One cardiologist described the device as a "significant step forward" for patients with heart disease. 

Researchers tracked recent TAVR data from the STS/ACC TVT Registry, highlighting a "concerning" finding they were unable to explain.

Most cardiac devices do not fit young children, making it especially important for growth in pediatric cardiology to continue. The FDA helped fund a contest aimed at identifying new devices that show a ton of potential.